367 related articles for article (PubMed ID: 31536686)
1. Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
Kane JM; Correll CU
J Clin Psychiatry; 2019 Sep; 80(5):. PubMed ID: 31536686
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
3. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.
Kane JM; McEvoy JP; Correll CU; Llorca PM
CNS Drugs; 2021 Nov; 35(11):1189-1205. PubMed ID: 34636025
[TBL] [Abstract][Full Text] [Related]
4. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
Correll CU; Lauriello J
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609958
[TBL] [Abstract][Full Text] [Related]
5. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence.
Correll CU; Citrome L; Haddad PM; Lauriello J; Olfson M; Calloway SM; Kane JM
J Clin Psychiatry; 2016; 77(suppl 3):1-24. PubMed ID: 27732772
[TBL] [Abstract][Full Text] [Related]
6. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges.
Haddad PM; Correll CU
Expert Opin Pharmacother; 2023 Mar; 24(4):473-493. PubMed ID: 36919576
[TBL] [Abstract][Full Text] [Related]
7. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
[TBL] [Abstract][Full Text] [Related]
8. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
9. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry.
Kane JM; Kishimoto T; Correll CU
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S37-41. PubMed ID: 23849151
[TBL] [Abstract][Full Text] [Related]
10. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
[TBL] [Abstract][Full Text] [Related]
11. Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?
Perkins DO
J Clin Psychiatry; 2017; 78(9):e1431. PubMed ID: 29345879
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
Stevens GL; Dawson G; Zummo J
Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
[TBL] [Abstract][Full Text] [Related]
14. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives.
Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
Can J Psychiatry; 2013 May; 58(5 Suppl 1):23S-9S. PubMed ID: 23945064
[TBL] [Abstract][Full Text] [Related]
15. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
Graffino M; Montemagni C; Mingrone C; Rocca P
Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
17. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
Correll CU
J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
[TBL] [Abstract][Full Text] [Related]
18. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Buckley PF; Schooler NR; Goff DC; Hsiao J; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz AJ; Miller del D; Severe JB; Wilson DR; Ames D; Bustillo J; Mintz J; Kane JM;
Schizophr Bull; 2015 Mar; 41(2):449-59. PubMed ID: 24870446
[TBL] [Abstract][Full Text] [Related]
19. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
[TBL] [Abstract][Full Text] [Related]
20. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years.
Patel MX; Haddad PM; Chaudhry IB; McLoughlin S; Husain N; David AS
J Psychopharmacol; 2010 Oct; 24(10):1473-82. PubMed ID: 19477883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
